advertisement

Digestive-Health

08 November 2011

Erbitux approval expanded

Most common in men, people older than 50.

MONDAY, Nov. 7 (HealthDay News) -- U.S. Food and Drug Administration approval of Erbitux (cetuximab) has been expanded to include late-stage (metastatic) head and neck cancer, the agency announced Monday.

Head and neck cancer accounts for up to 5 percent of all cancer cases in the United States, and is most common in men and in people older than age 50, the FDA said, citing statistics from the U.S. National Cancer Institute.

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.